EUVIMEDEUVIMED entdecken
Crossref

Rational design of selective bispecific EPO-R/CD131 agonists

Kailyn E Doiron iD, Jeffrey C Way iD, Pamela A Silver iD

Protein Engineering, Design and Selection · 2025

DOI: 10.1093/protein/gzaf013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Engineering, Design and Selection, 2025. Verfasst von Kailyn E Doiron und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, Harvard Medical School, 210 Longwood Avenue, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Receptors, Erythropoietin, Antibodies, Bispecific, Cytokine Receptor Common beta Subunit, Drug Design. Die Arbeit nennt 69 Literaturangaben. Gefördert von: Department of Defense, Henry Jackson Foundation, Air Force Research Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Erythropoietin (EPO) suppresses apoptosis and promotes survival by signaling through EPO-R/EPO-R on hematopoietic progenitors or EPO-R/CD131 on non-hematopoietic cells. However, EPO signaling through EPO-R/CD131 is controversial and there is no solved structure of a complex. Here, we constructed a structural model of EPO-R/CD131 and designed several anti-EPO-R, anti-CD131 bispecific proteins that selectively activate EPO-R/CD131. Treatment with these fusion proteins is sufficient to activate STAT5 phosphorylation downstream of EPO-R/CD131 without engaging EPO-R/EPO-R. We demonstrated that proteins with a tandem scFv or bispecific antibody format activate EPO-R/CD131, in contrast to an equimolar mixture of the individual scFvs. Finally, we explored the effect of modifications to binding domain arrangement and linker length and found results consistent with our structural model of an EPO-R/CD131 complex. These findings highlight the utility of bispecific scaffolds in the development of cytokine receptor agonists and provide a foundation for the study of EPO-R/CD131 biology and future clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ErythropoietinAntibodies, BispecificCytokine Receptor Common beta SubunitDrug DesignHumansModels, MolecularProtein EngineeringSTAT5 Transcription FactorErythropoietin

Stichwörter der Autor:innen

CytokineErythropoietinNeuroprotectionSTAT5scFv

Substanzen

Receptors, ErythropoietinAntibodies, BispecificCytokine Receptor Common beta SubunitSTAT5 Transcription FactorErythropoietin

Autor:innen und Institutionen

  • Department of Systems Biology, Harvard Medical School, 210 Longwood Avenue, Boston, MA 02115, USA.
  • Wyss Institute for Biologically Inspired Engineering, 201 Brookline Avenue, Boston, MA 02215, USA.
  • Harvard Systems, Synthetic and Quantitative Biology PhD Program, Harvard Medical School, 210 Longwood Avenue, Boston, MA 02115, USA.

ORCID-Profile: Kailyn E Doiron, Jeffrey C Way, Pamela A Silver

Förderung

  • Department of Defense
  • Henry Jackson Foundation
  • Air Force Research Laboratory
  • NIGMS NIH HHS

Zitieren

APA

Doiron, K. E., Way, J. C., & Silver, P. A. (2025). Rational design of selective bispecific EPO-R/CD131 agonists. Protein Engineering, Design and Selection. https://doi.org/10.1093/protein/gzaf013

Vancouver

Doiron KE, Way JC, Silver PA. Rational design of selective bispecific EPO-R/CD131 agonists. Protein Engineering, Design and Selection. 2025. doi:10.1093/protein/gzaf013

BibTeX
@article{Doiron2025,
  author = {Doiron, Kailyn E and Way, Jeffrey C and Silver, Pamela A},
  title = {Rational design of selective bispecific EPO-R/CD131 agonists},
  journal = {Protein Engineering, Design and Selection},
  year = {2025},
  doi = {10.1093/protein/gzaf013}
}
Kostenlos starten →